|
subsections menu :
Contacts
|
Content :
Press releases 2006
December 28, 2006 Canadian Federal Court of Appeals rules in sanofi-aventis’ favor in the Canadian Plavix Notice of Compliance proceedings
December 20, 2006 Sanofi pasteur influenza vaccine production tops 170 million doses in 2006
December 15, 2006 Sanofi-aventis statement regarding U.S. FDA Joint Advisory Committee recommendation for Ketek® (telithromycin)
December 14, 2006 New organization announced for January 1st, 2007
December 14, 2006 Taxotere®-based regimens with Herceptin® in women with early-stage HER2-positive breast cancer demonstrate the highest reduction in the risk of death to date and provide a treatment option without anthracyclines
December 12, 2006 New study shows Clexane® / Lovenox® (enoxaparin sodium injection) is more effective than unfractionated heparin (UFH) for preventing the risk of venous thromboembolism (VTE) in patients with acute ischemic stroke
December 10, 2006 Idraparinux shows encouraging results in Van Gogh clinical trials program
December 8, 2006 Rimonabant update in the United States
December 8, 2006 Preliminary Injunction Against Apotex Upheld on Appeal
December 5, 2006 New data shows ACOMPLIA® (rimonabant) benefited patients with type 2 diabetes by improving blood sugar control, reducing weight and acting on other cardiometabolic risk factors
November 29, 2006 Sanofi-aventis receives pediatric exclusivity for AMBIEN® and AMBIEN® CR
November 27, 2006 Sanofi pasteur completes shipment of 50 million doses of influenza vaccine
November 20, 2006 Sanofi pasteur signs contract with U.S. government for stockpile of new type of H5N1 pre-pandemic vaccine
November 13, 2006 Sanofi-aventis, Innogenetics, and Inserm to collaborate on Alzheimer’s disease
November 10, 2006 Sweden grants reimbursement of Acomplia™ (rimonabant) for overweight patients with associated risk factors
November 9, 2006 Acomplia™ receives 1st marketing authorisation in the North American continent
October 31, 2006 First 9 months of 2006: Sales growth of 2.6% on a comparable basis - Adjusted EPS growth of 15.0%, or 7.5% excluding selected items
October 27, 2006 The Lancet publishes RIO-Diabetes study
October 26, 2006 New Head of sanofi-aventis Communications Department
October 25, 2006 The commercial subsidiary of sanofi-aventis in France is presenting a reorganisation plan resulting in the loss of 504 posts
October 18, 2006 Sanofi-aventis objects to the recommendation of the German Federal Joint Committee (“Gemeinsamer Bundesausschuss” – “G-BA”) regarding Acomplia
October 18, 2006 Sanofi Pasteur H5N1 pre-pandemic vaccine neutralizes additional circulating H5N1 virus
October 18, 2006 Taxotere® receives U.S. FDA approval for the treatment of patients with head and neck cancer
October 17, 2006 Sanofi-aventis has sold its entire stake in Rhodia
October 17, 2006 Sanofi-aventis announces the sale of its stake in Rhodia
October 13, 2006 Positive interim efficacy results from large randomized adjuvant gastric cancer trial
October 10, 2006 Sanofi-aventis strengthens its commitment with the World Health Organization (WHO) to fight neglected tropical diseases
October 2, 2006 Childhood cancers: second call for projects "My Child Matters"
September 25, 2006 Sanofi-aventis and UCB sign a co-promotion agreement for Xyzal® in the United States
September 22, 2006 TAXOTERE® receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending approval in the European Union for head and neck cancer
September 21, 2006 Plavix® Preliminary Injunction Appeal
September 19, 2006 Sanofi pasteur broadens pandemic preparedness with first clinical trial of novel cell based H7N1 vaccine
September 13, 2006 Sanofi-aventis prevails in arbitration against Rhodia
September 11, 2006 New Head of sanofi-aventis Human Resources Department
September 7, 2006 European commission expands indication for PLAVIX® (clopidogrel bisulfate) offering new option for patients with most severe type of heart attack
September 7, 2006 Sanofi-aventis withdraws European application for marketing authorization for dronedarone (MULTAQ™) in the treatment of Atrial Fibrillation/Atrial Flutter
September 4, 2006 New clinical data show enoxaparin significantly reduces the risk of repeat heart attacks and stroke in patients undergoing percutaneous coronary intervention (PCI)
September 1, 2006 Preliminary injunction ordered in PLAVIX® patent infringement case - Apotex to halt sales of unauthorized generic
September 1, 2006 Revised guidance for 2006
August 31, 2006 New trial date set for Lovenox® patent infringement suit
August 31, 2006 Sanofi-aventis receives a non approvable letter from the FDA for dronedarone (MULTAQ™) in the treatment of Atrial Fibrillation/Atrial Flutter - New filing expected during the first semester of 2008
August 17, 2006 FDA approves new indication for PLAVIX® (clopidogrel bisulfate) offering new option for patients with most severe type of heart attack
August 14, 2006 Motion filed for preliminary injunction in PLAVIX® patent infringement case
August 10, 2006 Trial date set for LOVENOX® patent infringement suit
August 8, 2006 Update regarding PLAVIX® patent infrigement case
August 4, 2006 Availability on-line of the Group’s interim report for the first half of 2006
August 2, 2006 First half of 2006: Sales growth of 7.7% on a reported basis and 4.5% on a comparable basis - Adjusted EPS growth of 32.9%, or 16.1% excluding selected items
July 28, 2006 PLAVIX® litigation settlement fails to receive antitrust clearance from states attorneys general
July 27, 2006 Update on PLAVIX® litigation settlement
July 20, 2006 Sanofi-aventis responds to the emergency request for humanitarian aid to Lebanon
July 3, 2006 Sanofi-aventis and Taiho sign an agreement for the development and marketing of an oral anticancer agent: S-1
June 29, 2006 Sanofi-aventis announces update to KETEK® (telithromycin) U.S. prescribing information
June 25, 2006 Update on PLAVIX® litigation settlement
June 21, 2006 ACOMPLIA® (rimonabant) receives marketing authorisation in the European Union
June 13, 2006 New study shows insulin glargine (LANTUS®) as effective and better tolerated than the prandial insulin lispro in initiating insulin therapy in type 2 diabetes
June 10, 2006 New study shows an innovative mealtime insulin dosing algorithm may provide a safe and effective alternative to carbohydrate counting for patients with type 2 diabetes
June 7, 2006 Study findings presented on TAXOTERE® regimens in head and neck, lung and breast cancer
June 5, 2006 Studies evaluating ELOXATIN®-based regimens in gastrointestinal cancers presented at the 42nd annual meeting of the American Society of Clinical Oncology (ASCO)
June 3, 2006 Results of a meta-analysis show benefits of Taxotere® (docetaxel) regimens in patients with advanced non-small cell lung cancer (NSCLC)
June 1, 2006 General Meeting of Shareholders
May 30, 2006 New Eloxatin® and Taxotere® data in several tumor types to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO)
May 11, 2006 Adjuvanted formulation of Sanofi Pasteur H5N1 pandemic influenza vaccine candidate demonstrates significant immune response
May 9, 2006 PLAVIX® (clopidogrel) launched in Japan
May 5, 2006 First quarter of 2006: Sales growth of 9.6% on a reported basis and 4.9% on a comparable basis. 52.8% growth in adjusted EPS and 19.8% excluding selected items.
April 28, 2006 Acomplia® (rimonabant) recommended for approval in the European Union
April 12, 2006 Transfer of all Japanese rimonabant rights to Sanofi-aventis
April 10, 2006 Appeals court rules in Sanofi-aventis’ favor in the U.S. Lovenox® (enoxaparin sodium) patent infringement case
April 3, 2006 Lantus®: publication of the LANMET study results
March 31, 2006 Filing of the 2005 U.S. Form 20-F and French ''Document de Référence''
March 27, 2006 Sanofi-aventis acquires 24.876% of Zentiva and becomes its largest shareholder
March 24, 2006 TAXOTERE® receives positive opinion from the Committee for Medicinal Products for Human Use recommending approval in the European Union for metastatic stomach cancer
March 23, 2006 TAXOTERE® receives U.S. FDA approval for use in advanced stomach cancer
March 21, 2006 Sanofi-aventis and Bristol-Myers Squibb announce agreement to settle U.S. Plavix® litigation with Apotex subject to certain conditions
March 21, 2006 Press release - Plavix®: Questions and Answers
March 16, 2006 Agreement between Sanofi-aventis and Roche to produce shikimic acid
March 12, 2006 New study furthers understanding of the role of dual antiplatelet therapy in the prevention of atherothrombotic events, including heart attack, stroke or cardiovascular death in broad population
February 28, 2006 Rescheduling of the trial date in the United States PLAVIX® litigation
February 28, 2006 Apidra® – A New Rapid-Acting Insulin Analog – is Now Available in the United States for Hyperglycemia in Adults with Type 2 and Type 1 Diabetes
February 24, 2006 Strong growth of 25.7% in 2005 adjusted EPS - Nearly 90% of synergies delivered by end 2005 - Dividend increased by 26.7%
February 17, 2006 Sanofi-aventis received from the FDA an approvable letter for rimonabant for weight management and a non approvable letter for smoking cessation
February 14, 2006 The Journal of the American Medical Association publishes the RIO-North America study
February 10, 2006 Sanofi-aventis voluntarily recalls 30 batches of enoxaparin syringes as a precautionary measure
February 6, 2006 Sanofi pasteur delivers more H5N1 vaccine for U.S. government pandemic initiatives
January 31, 2006 ''My child matters'': launch of a mobilisation campaign against childhood cancer in emerging countries
January 30, 2006 Dynamic growth in 2005 full-year consolidated net sales: up 9.3% on a comparable basis - Excellent performance from vaccines: up 26.9% on a comparable basis - 2005 adjusted earnings guidance raised - Approval of Plavix® in Japan
January 28, 2006 Xaliproden: final results of the Xenox clinical trial announced
January 24, 2006 PLAVIX®: Sanofi-aventis statement
January 24, 2006 PLAVIX® approved in Japan
January 18, 2006 FDA grants priority review to PLAVIX® (clopidogrel bisulfate) supplemental new drug application (sNDA) for additional type of heart attack
January 13, 2006 Pfizer to purchase sanofi-aventis rights to EXUBERA® in application of change of control clauses
January 11, 2006 FDA issues a written request for pediatric studies for zolpidem
|
Slots : |
Press releases and press packs are intended to journalists, investors and shareholders.
